Index

Note to index: An f following a page number designates a figure; a t following a page number indicates a table.

α[alpha], 380. See also hypothesis testing
β[beta], 381–82. See also hypothesis testing
adherence, 168–71, 284–94
  adherence assessment, 286–89
  to clinical schedule, 289
  with direct observation, 286–88
  without direct observation, 288–89
efficacy vs. effectiveness, 284–86
ethical issues, 293–94
  key points, 294
  measures to improve, 289, 293
  per protocol analysis, 285–86
  See also recruitment and retention
  allocation bias. See prognostic bias
alternative hypothesis, 378. See also hypothesis testing
analysis bias, 212–13
archiving requirements, 372
assent, 39. See also informed consent
  assessor
  bias, 211–12, 222
  training of, 223–24
authorization form for protecting data, 18, 36–37
avoiding bias. See bias, avoiding
Belmont Report, 16–17
bias, 203–16
  analysis bias, 212–13
  assessor bias, 211–12
  avoiding
  assessment methods and training, 223–24
  blinding (masking), 143–44, 221–22
  data monitoring during study, 224–25
  ethical issues, 225–26
  key points, 226
  population selection, 217–19
  randomization, 143–44, 219–21
  care provider bias, 210–11
  in case-control study, 204–05, 218, 222, 307–08, 315
  in cohort study, 222
  common sources, 203–13
  and data storage, 371
  ethical issues, 214–15
Index

404

bias (cont.)

historical controls, 206, 219, 317–18
and hypothesis testing, 387
interpretation bias, 213
in interventional study, 143–44
in interviews, 219, 223
key points, 215–16
laboratory bias, 212
learning effect, 209–10, 224
non-differential bias, 214
overlap among types of, 203
participant bias, 208
prognostic bias, 204–06
publication bias, 203, 213, 215
random variation vs., 203
and randomization (see randomization)
recall bias, 208–09, 218–19, 301–02
rater bias, 211–12
selection bias, 206–08
underreporting as, 209, 308
See also ethics; randomization; validity
binary variables, 175, 190–91
blinding, 258–69
breaking the blind, 266–68
ethical issues, 268
hierarchy of, 259–66
complete blinding, 261–62
double-blind study, 260–61, 334
open-label study, 264–66
in interventional study (see blinding techniques for interventional study)
single-blind study, 262–64
key points, 269
level of blinding, multiple, 266
in observational study, 334–39
ethical issues, 338
key points, 339
maintaining the blind, 335–37
what to blind, 334
when not possible, what to do, 337–38
reasons to use, 143–44, 221–22, 258–59
blinding techniques for interventional study,
270–83
common problems maintaining blinding, 279–81
efficacy, 280
leaks and guesses, 281
side effects, 279–80
of data management staff, 275
ethical issues, 281–82
of intervention, 270–75
non-pharmaceutical intervention, 273–74
pharmaceutical intervention, 270–73
key points, 282–83
of laboratory staff, 274–75
goal, 276
of treatment, 270–75
non-pharmaceutical treatment, 273–74
pharmaceutical treatment, 270–73
treatment provision, 275–78
by institutional pharmacist, 276–77
by manufacturer, 276
by study team, 277–78
benefits and pitfalls with, 254–55
and interim analyses, 253
reason for, 250
breaking the blind, 266–68
care provider bias, 210–11
carryover effect, 75. See also crossover study
case-cohort study, 127–28
case-control study, 51–52 95–103
advantages of, 86, 100–01
basic design of, 95–97
bias in, 204–05, 208–09, 218, 222, 307–08, 315
cohort study vs., 100–01, 127–29
control groups, multiple, 96–97, 316
concurrent vs. historical controls, 95
data issues in, 114–15, 128–29
disadvantages of, 100–01
ethical issues, 102
key points, 102–03
matching in, 98–99, 321–33
  frequency matching, 99, 328–29
  individual matching, 98–99, 321–33
nested, 99–101, 127
participant recruitment, 128
record reviews as, 112, 130, 132
research question as determinant of, 54, 119–20
resource issues, 124
time considerations, 129
uses of, 95
variables in, 182
verification of data, 371
See also case-control study, participant identification; matching
case-control study, participant identification, 97–98, 307–20
case identification, 97, 308–10
control identification, 311–13
general considerations, 97–98
multiple control groups, 96–97, 316
ethical issues, 319
general considerations, 307–08
bias, 307–08, 315
historical controls, 317–18
inclusion and exclusion criteria for controls, 313–16
  and bias, 315
and definition of “normal or healthy,” 155–56, 314–15
and definition of “standard,” 315
key points, 319–20
nested, 317
sample size, 318–19
special situations, 316–18
case series study. See single arm study
censored data, 193
children
  age as inclusion and exclusion criterion, 152
  and assent, 39
  exclusion from study, 158–59
  and informed consent, 35, 38–39, 149, 158
clinical equipoise, 121
clinical importance vs. statistical significance, 380
clinical trials, 52–53
  phases of, 53
code book, 362
coding, data, 184, 191–92
coercion, 37. See also informed consent
cohort study, 50–51, 82–94
  advantages compared to interventional study, 86–87
  basic designs, 82–86
  and blinding, 222
case-control study vs., 100–01, 127–29
concurrent, 82–83 (see also prospective cohort study)
cross-sectional study vs., 108
data problems in, 114
disadvantages compared to interventional study, 87–89
ethical issues, 92–93
historical, 82–83 (see also retrospective cohort study)
key points, 93–94
outcome variables, 192
cohort study (cont.)
participant recruitment, 128, 299–300, 304–05
prognostic bias in, 205–06
prospective 82–83 (see also prospective cohort study)
retrospective cohort study, 82–83 (see also retrospective cohort study)
variables in, 181, 182, 192, 197
verification of data, 371
See also cohort study, participant identification; record review
cohort study, participant identification, 297–306
comparative cohort study, 304–05
data
availability, 297–300
completeness, 302
quality, 300
in prospective study, 297–98, 299
in retrospective study, 298, 299
sources, 299
ethical issues, 305–06
key points, 306
multiple cohort study, 304–05
stratified sampling, 299–300
study time line, 302–04
Common Rule (The Federal Policy for the Protection of Human Subjects), 17, 23, 118
comparative cohort study, 86
compensation for participants, 16, 30–31, 169
compliance. See adherence
computers
and confidentiality, 372, 373
and data storage, 358–74
 programs for, 249
concomitant variables. See predictor and confounding variables
confidentiality, 22
in case-control study, 308–10
communication with participants general, 171
and Internet communication with participants, 172
in cohort study, 305
and data storage, 371–73 (see also data storage: confidentiality)
informed consent, 31, 34
examples of, 34
record review, 118
during recruitment and retention, 171–72, 173
Study ID, 246, 343–44, 372
See also informed consent
conflict of interest, 36
confounding variables. See predictor and confounding variables
consent. See informed consent
case group
in case-control study, 97–98 (see also case-control study, participant identification)
in comparative cohort study, 304–05
in interventional study (see randomization)
intervention, 229–36 (see also intervention, control)
convenience allocation as not randomization, 242
Council for International Organizations of Medical Sciences (CIOMS), 15
crossover study, 48–49, 53, 74–77
AB/BA design, 74–75
ethical issues, 80
participant recruitment, 76–77
problems with, 75–76
study question for, 63, 64
cross-sectional study, 52, 104–10
cohort study vs., 108
common problems in, 108–09
ethical issues, 109–10
key points, 110
See also record review
databases. 358–61
data collection, 343–57
ethical issues, 355–56
key points, 356–57
Manual of Procedures (MOP), 176, 183, 351, 354
methods, 344–52
biological tests, 351
interviews (see interviews)
other types of procedures, 351–52
questionnaires (see questionnaires)
smartphones 345–46
tables 345–46
noise in, 214, 392
Study ID, 246, 343–44, 372
See also data storage; variables
data dredging, 194, 212–13, 387
Data Safety and Monitoring Board (DSMB), 14,
25–26, 213, 267, 280
data storage, 184–85, 358–74
basic approaches to, 358–61
analysis programs, 361
relational databases, 359, 360–61
spreadsheets, 359, 360, 361
capturing data for storage, 365–67
confidentiality, 371–73
archiving requirements, 372
computer records, 372
and data sharing, 372–73
images, 372
participant right to withdraw use of data, 372
and Study ID, 372
documenting data, 362
ethical issues, 373
key points, 374
numeric vs. alphabetic codes, 369
program selection, 364–65
terminology for, 358
verifying data, 367–71
and bias, 371
abstraction of source documents, 367–68
comparison of computer data to original records, 368
consistency and plausibility, 367, 368–70
uncorrectable variables, 370–71
Declarations of Helsinki, 15–16
Department of Health and Human Services (HHS), 17, 18, 26, 38
dependent variables. See outcome variables
derived outcomes, 184, 190–92. See also outcome variables
design development
interventional study, 69–71
multiple designs considered, 130–32
record review, 130–32
design selection, 119–33
ethical issues, 132–33
interventional compared to observational design, 54–57, 86–89
interventional study, 120–24
development, example, 69–71
ethical issues, 120
practicality of, 123
design selection (cont.)
  adequate number of participants, 124
  resource issues, 123–24
  time issues, 123
  selection of, 124–27
  parallel group study, 125
  pre-post study, 125–26
  randomized vs. non-randomized, 125–26
  single arm study, 125
  key points, 133
  multiple designs, 119–20, 130–32
  observational compared to interventional design, 54–57, 86–89
  observational study, 127–30
  adequate number of participants, 124
  case-control vs. cohort study, 100–01, 127–29
  ethical issues, 120
  prospective vs. retrospective cohort study, 90–92, 127–30
  resource issues, 123–24
  time issues, 123
  devices for data collection, 345–46
  dichotomous variables, 175, 190–91
  documentation. See authorization form for protecting data; informed consent document; institutional review board, approval
  double-blind study, 260–61. See also blinding
  dropouts
  large impact in crossover study, 76
  and number to be randomized, 247
  DSMB, 14, 25–26, 213, 267, 280
  economic issues
  and blinding, 281
  and generalizability, 141, 142
  effectiveness, 284–86
  efficacy, 284–86
  elderly persons
  recruitment of, 168
  electronic devices for data collection, 345–46
  endpoints. See outcome variables
  equivalence study, 63, 392
  errors, statistical. See hypothesis testing ethics, 14–27
  additional reading, 26
  addressing before start of research, 12–13
  adherence, 293–94
  case-control study, 102
  participant identification, 319
  cohort study, 92–93
  defining populations for, 305–06
  compliance, 293–94
  crossover study, 80
  cross-sectional study, 109–10
  data collection, 355–56
  Data Safety and Monitoring Board, 14, 25–26, 213, 267, 280
  data storage, 373
  design selection, 120, 132–33
  development of guidelines for, 14–18
  international codes, 15–16
  Council for International Organizations of Medical Sciences, 15
  Declaration of Helsinki, 15–16
  Nuremberg code, 15
  United States, 16–18
  Belmont Report, 16–17
  Health Insurance Portability and Accountability Act, 17–18
  National Research Act, 16–17
  Standards for Privacy of Individually Identifiable Health Information, 17–18
Index

duration of study, 194–95

generalizability, 144–45

informed consent, 42–43 (see also informed consent)

interventional study, 80, 120

IRB (see Institutional Review Board (IRB))

key points, 26–27

observational study, 92–93

blinding, 332–33

outcomes variables, 194–95

placebos, 281–82

principles, 18–22

fair subject selection, 20

favorable risk-benefit ratio, 21

independent review, 21

informed consent, 22 (see also informed consent)

respect for potential and enrolled subjects, 22

scientific validity, 19–20

social and clinical value, 18–19

record reviews, 118

recruiting and retaining participants, 172–73

resources for additional information, 26

safety variables, 185

sample size, adequacy of, 400

study design selection, 59–61

study population, 158–59

tissue samples, 41–42

validity, 145

variables, use of, 185

examples. See book website for searchable index

FDA, 18, 24, 215, 233

The Federal Policy for the Protection of Human Subjects (Common Rule), 17, 23, 118

fetuses and neonates, 31, 40–41

Food and Drug Administration (FDA), 18, 24, 26, 215, 233

frequency matching, 328–29

generalizability, 137–43

definition, 137

economic issues in, 141, 142

ethical issues, 144–45

key points, 145–46

and population studied, 137–40

study procedures, 140–43

assessment methods, 142–43

treatment and treatment monitoring, 140–42

See also validity

Health and Human Services (HHS), 17, 18, 26, 38

Health Insurance Portability and Accountability Act (HIPAA)

and data protection, 36–37, 298

and informed consent, 31–32, 35, 305

purpose of, 17–18

"healthy" control, definition of, 155–56, 314–15

HHS, 17, 18, 26, 38

HIPAA. See Health Insurance Portability and Accountability Act (HIPAA)

historical controls, 95, 206, 219, 317–18

hypothesis driven research, 7, 11–12

hypothesis testing, 377–89

alternative hypothesis, 378, 379–80

one-sided vs. two-sided, 379–80, 383, 388

criminal trial as analogy for, 377–78

ethical issues, 387–88

potential for bias, 387

testing until you find significance, 387–88

key points, 388–89

null hypothesis, 378, 379
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>419</td>
<td>P-value</td>
</tr>
<tr>
<td></td>
<td>382, 383–84</td>
</tr>
<tr>
<td>419</td>
<td>process</td>
</tr>
<tr>
<td></td>
<td>383–86</td>
</tr>
<tr>
<td>419</td>
<td>power</td>
</tr>
<tr>
<td></td>
<td>382</td>
</tr>
<tr>
<td>420</td>
<td>reject vs. fail to reject null hypothesis</td>
</tr>
<tr>
<td></td>
<td>378–79</td>
</tr>
<tr>
<td>420</td>
<td>statistical significance vs. clinical importance</td>
</tr>
<tr>
<td></td>
<td>380</td>
</tr>
<tr>
<td>420</td>
<td>determining</td>
</tr>
<tr>
<td></td>
<td>383–86</td>
</tr>
<tr>
<td>420</td>
<td>Type I error</td>
</tr>
<tr>
<td></td>
<td>380–81</td>
</tr>
<tr>
<td>420</td>
<td>Type II error</td>
</tr>
<tr>
<td></td>
<td>381–82</td>
</tr>
<tr>
<td>420</td>
<td>inclusion and exclusion criteria. See study population</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>420</td>
<td>independent review</td>
</tr>
<tr>
<td></td>
<td>21</td>
</tr>
<tr>
<td>420</td>
<td>independent variables. See predictor and confounding variables</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>420</td>
<td>informed consent</td>
</tr>
<tr>
<td></td>
<td>22, 28–43</td>
</tr>
<tr>
<td>420</td>
<td>and coercion</td>
</tr>
<tr>
<td></td>
<td>37</td>
</tr>
<tr>
<td>420</td>
<td>and cohort study</td>
</tr>
<tr>
<td></td>
<td>305</td>
</tr>
<tr>
<td>420</td>
<td>and confidentiality</td>
</tr>
<tr>
<td></td>
<td>31</td>
</tr>
<tr>
<td>420</td>
<td>ethical issues</td>
</tr>
<tr>
<td></td>
<td>22, 42–43</td>
</tr>
<tr>
<td>420</td>
<td>exemption or postponement of informed consent</td>
</tr>
<tr>
<td></td>
<td>42, 149</td>
</tr>
<tr>
<td>420</td>
<td>and IRBs</td>
</tr>
<tr>
<td></td>
<td>24, 42</td>
</tr>
<tr>
<td>420</td>
<td>key points</td>
</tr>
<tr>
<td></td>
<td>43</td>
</tr>
<tr>
<td>420</td>
<td>process</td>
</tr>
<tr>
<td></td>
<td>28–36</td>
</tr>
<tr>
<td>420</td>
<td>consent document</td>
</tr>
<tr>
<td></td>
<td>29–34</td>
</tr>
<tr>
<td>420</td>
<td>interview</td>
</tr>
<tr>
<td></td>
<td>34–36</td>
</tr>
<tr>
<td>420</td>
<td>special populations</td>
</tr>
<tr>
<td></td>
<td>38–41</td>
</tr>
<tr>
<td>420</td>
<td>children</td>
</tr>
<tr>
<td></td>
<td>35, 38–39, 149, 158</td>
</tr>
<tr>
<td>420</td>
<td>persons unable to understand and agree to study</td>
</tr>
<tr>
<td></td>
<td>39, 149, 158</td>
</tr>
<tr>
<td>420</td>
<td>pregnant women, fetuses, neonates</td>
</tr>
<tr>
<td></td>
<td>31, 40–41</td>
</tr>
<tr>
<td>420</td>
<td>prisoners</td>
</tr>
<tr>
<td></td>
<td>41</td>
</tr>
<tr>
<td>420</td>
<td>speakers of other languages</td>
</tr>
<tr>
<td></td>
<td>35, 40</td>
</tr>
<tr>
<td>420</td>
<td>for tissue sample use and retention</td>
</tr>
<tr>
<td></td>
<td>41–42</td>
</tr>
</tbody>
</table>

hypothesis testing (cont.)

overview of, 378–82
power, 382
reject vs. fail to reject null hypothesis, 378–79
statistical significance vs. clinical importance, 380
determining, 383–86
Type I error, 380–81
Type II error, 381–82

waiver of informed consent, 42, 118, 123
and undue influence, 37–38
See also informed consent document;
Institutional Review Board (IRB)

informed consent document
authorization form for protecting data, 18, 36–37
elements of, 30–32
examples of text for confidentiality, 34
investigator and participant interactions at end of study, 33
procedures in study, 32–33
restrictions on immediate withdrawal from study, 33–34
language used in, 29
level of detail expected, 32–33
and reading level of participant, 29–30
release to use data, included in 18, 36–37
templates for, 30, 32
institutional questionnaires, 346
Institutional Review Board (IRB), 14, 16, 18
approval required for
cross-sectional study, 109
cohort study, 298, 305
interventional study, 58, 123
record review, 111, 115, 118
composition of, 23–24
establishment of, 23
exemption or postponement of informed consent, 42, 149
and financial compensation for participants, 169, 173
overview of, 23–24
private for-profit, 23
purpose of, 24
responsibilities of, 24
Index

411

and risk-benefit ratio, 58, 60–61
and safety monitoring plan, 180
and special populations, 38, 40
and undue influence, 37–38
and waiver of informed consent, 42, 118, 123
See also Data Safety and Monitoring Board (DSMB); ethics

internet communication with participants, 172
interpretation bias, 213
intervention, control, 229–36
describing, 234–35
active controlled study, 234
placebo controlled study, 234
ethical issues, 235
placebo control group, 235
key points, 235–36
problems in, 229–31
standard of care, 230–31
taking of medication, 229–30
selecting, 231–33
active control group, 231, 233
placebo control group, 231, 232–33
See also interventional study

interventional study, 62–81
advantages of, 57
bias in, 143–44
avoiding (see blinding techniques for interventional study)
types of
historical controls, 219
learning effect, 209–10
prognostic, 204
recall, 208
blinding in (see blinding)
blinding techniques for, 270–75 (see also
blinding techniques for interventional study)
case series study, 64–66 (see also single arm study)
confounding variables in, 178
crossover study 74–77 (see also crossover study)
ethics, 59–61, 80, 120
focus of, 47
key points, 61, 81
outcome variables in 177 (see also outcome variables)
overview of, 47–49, 62–63
parallel group study 69 69–70 (see also parallel group study)
participants, all receive intervention, 64–68
with randomization
crossover study 74–77 (see also crossover study)
without randomization
pre-post study 77–79
single arm study, 47–48, 64–66 (see also single arm study)
participants, some receive intervention 68–74
parallel group study 69–70 (see also parallel group study)
participants with and without intervention, 74–79
with randomization
crossover study, 74–77 (see also crossover study)
without randomization
pre-post study, 77–79
predictor variables in, 196
pre-post study, 77–79
randomization in, 48
with randomized intervention
interventional study (cont.)
crossover study, 74–77 (see also crossover study)
parallel group study, 69–70 (see also parallel group study)
without randomized intervention
pre-post study, 77–79
single arm study, 47–48, 64–66 (see also single arm study)
and risk-benefit ratio, 122
safety variables in, 179
single arm study, 64–66 (see also single arm study)
summary of, 47–49, 62–63
time line for, 302–03
variables in, 176–81
confounding, 178
outcome, 177
predictor, 177–78, 196
predictor vs. confounding variable, 181
role of variables, 180–81
safety, 178
and verification of data, 371
See also randomization; blinding
interviews
and blinding, 336–37
free-form, 348–51
interviewer training, 350–51
language issues, 351
transcribing and coding, 349–50
structured, 349
and bias, reducing, 219, 223
and cross-training of raters, 223–24
as data collection instrument, 345
scoring of, 349
laboratory bias, 212
language issues. See speakers of foreign languages
learning effect, bias due to, 209–10, 224
list matching, 325
Manual of Procedures (MOP), 176, 183, 351, 354
masking. See blinding
matching, 321–33
definition, 321
ethical issues, 332–33
frequency matching, 328–29
index group, 322–23
individual matching, 325–28
choosing between eligible controls, 327–28
using distinct characteristics, 327
using scores, 327–28
defining matching criteria, 325–27
using difference score, 326
using distinct characteristics, 325–26
using propensity score, 326–27
using variable scores, 326
key points, 333
list matching, 325
practical issues, 329–32
appropriate controls, lack of, 331–32
data analysis, 332
excessive matching criteria, 330
overmatching, 329–30
recruitment of controls from general population, 331
selection of controls from databases, 330–31
reasons to use, 321–22
when done, 323–25
in analysis phase, 324–25
in recruitment phase, 323–24
minimizing bias. See bias, avoiding
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 16–17
National Institutes of Health (NIH), 23, 26
neonates and fetuses, 31, 40–41, 152
nested case-control study, 63, 99–101, 127
NIH (National Institutes of Health), 23, 26
noise in data, 214, 392. See also sample size
non-differential bias, 214
non-inferiority boundary, 233
non-inferiority study, 63, 71–72, 392
“normal” control, definition of, 155–56, 314–15
null hypothesis, 378. See also hypothesis testing
Nuremberg code, 15

observational study
bias in
assessor, 211–12
historical controls, 219
prognostic, 204–06
recall, 208–09
blinding in, 334–39
ethical issues, 338
key points, 339
maintaining the blind, 335–37
what to blind, 334
when not possible, what to do, 337–38
case-control study, 96 (see also case-control study)
case-control vs. cohort study 100–01, 127–29
cohort study, 82–83 (see also cohort study; prospective cohort study; retrospective cohort study)
cross-sectional study, 105 (see also cross-sectional study)
designs for, 49–52
ethical issues, 92–93, 102, 118
and informed consent, 30
key points, 93–94, 102–03, 110, 118
record review, 115, 116 (see also record review)
retrospective vs. prospective cohort study, 90–92, 127–30
selection of exposures, 49–50
variables, 181–82
See also case-control study; cohort study; cross-sectional study; prospective cohort study
Office for Human Research Protection (OHRP), 26
open label extension, 73
open label study, 264–66. See also blinding
outcome variables, 177, 187–95
and data recoding, 184, 191–92
and data relevance, 188
defining, 187–90
derived, 188–89, 190–92
changes over time, 192
dichotomous outcomes, 190–91
efficacy, distinguishing from safety variables, 187
ethical issues, 194–95
and frequency of measurements, 190
in interventional study, 188, 198
key points, 195
multiple equally important, 189
in observational study, 182, 189
as predictor variables, 180–81, 197–98
primary vs. secondary, 177
safety variables as, 178, 180
specifying in advance of study, 187–88, 194
surrogate, 193–95
time-related outcomes, 192–94
time-to-event, 193
time trends, 192–93
unexpected results, 194
overmatching, 329–30
paper-based questionnaires, 345
parallel group study, 69–70
basic design, 48–49, 68–74
and blinding, 68–69
and clinical trials, 53
drop out problem in, 70
ethical issues, 80
with extension, 73 72–73
intervention vs. control group in, 68
and randomization, 68, 73–74
selection of, 124–27
variables, uses of, 175–76, 188,
197, 198
See also interventional study
pharmaceutical interventions
and blinding, 261, 270–72, 276–77
and pregnancy, 155
Phase 1 clinical trial, 53, 264–66
Phase 2 clinical trial, 53
Phase 3 clinical trial, 53
Phase 4 clinical trial, 53
PHI (Protected Health Information), 17–18
pilot study, 264–66
placebo control study, 231, 232–33, 234, 235
placebos
as control group 231, 232–33, 234, 235
eethical issues with, 281–82
population. See special populations; study population
post-marketing study, 53
power, 382. See also hypothesis testing
post-hoc matching, 324–25
predictor and confounding variables, 178, 196–202
confounding variables, 198–99
examples of, 199
in observational study, 182, 199
distinction between, 181, 199–200
ethical issues, 200–01
and excessive data collection, 201
need to collect, 185
in interventional study, 181
key points, 201–02
in observational study, 322
predictor variables, 177–78, 196–98
in interventional study, 196, 197, 198
outcome variables as, 180–81, 197–98
in observational study, 196
primary and secondary, 177–78
specifying in advance of study, 196, 200–01
pregnancy
and informed consent, 31, 40–41
and pharmaceutical interventions, 155
pre-post study, 77–79
prisoners, and informed consent, 41
privacy 17–18, 24, 298, 372.
See also confidentiality
authorization form for protecting data, 18,
36–37
prognostic bias, 204–06, 219–21
prognostic variables, 240, 249–50
proof of concept study, 65
propensity score, 326–27
prospective cohort study, 82–83
comparative cohort study, 86
data quality issues, 129
long-term outcome, example, 83–84
recruitment for, 297–98, 299
resource issues in, 124
vs. retrospective, 90–92, 127–30
routinely collected data for, 85
short-term outcome, example, 84–85
study time line for, 303
time issues in, 129
See also cohort study
Protected Health Information (PHI), 17–18
Authorization Form for use of, 18, 36–37
publication bias, 203, 213, 215

question, research. See research question
questionnaires, 345–48
common problems, 108
as data collection instrument, 345
designing, 347–48
electronic devices, 345–46
formatting, 346
institutional, 346
language issues, 347–48
minimizing recall bias, 219
for subjective data, 346

random variation, bias vs., 203
randomization, 237–44
assessor bias, 243
and blinding, 238, 278
cost benefit allocation is not, 242
defining, 237–40
to eliminate bias, 143–44, 219–21, 240–42
prognostic bias, 238, 240, 241–42
prognostic variable balance, 240, 249–50
selection bias, 240–41
key points, 244
participant bias, 243
reasons for, 242–43
requirements for valid, 245–46
treatment unknown until participant enrolled in study, 246
techniques for (see randomization techniques)
unequal, 253, 255–56, 399
randomization techniques 245–57
ethical issues, 256–57
key points, 257
randomization schedule
adding special features to, 249–55
blocking, 252–54
benefits and pitfalls with, 254–55
and interim analyses, 253
reason for, 250
creation of, 246–49
randomization number, 246–47
Study ID number, 246
treatment assignment list, 248
treatment assignment numbers in, 247
treatment numbers of dropouts are not reused, 248–49
stratification, 250–52
benefits and pitfalls with, 254–55
defining strata, 250–51
separate randomization schedule for each stratum, 251–52
reason for, 250
randomized interventional study. See interventional study
randomized parallel group study. See parallel group study
rater bias, 211–12, 222
recall bias, 208–09, 218–19, 301–02
recoding variables, 184, 191–92
record review, 111–18
data
availability, 111–13
problems, 114–15
quality, 113
design development, example, 130–32
case-control study, 130, 132
morphing into prospective cohort study, 92, 131
retrospective cohort study, 130–31
Index

record review (cont.)
  ethical issues, 118
  IRB approval for, 111, 115
  key points, 118
  observational study, 52
  observational study, examples of, 115–18
  case-control study, 116, 117
  cross-sectional study, 115–17
  retrospective cohort study, 115–17
  recruitment and retention, 161–74
    as part of planning, 163–64
    longitudinal study, 163
    ethical issues, 172–73
    and generalizability, 137–40
    key points, 174
  methods, 164–68
    advantages and disadvantages of, 165–66
    from clinics, 164–66
    from cohort study, 128
    from databases, 330–31
    from general population, 166–67
    Internet, use of, 171–72
    random digit dialing, 167–68
    right number for, 161–63
    flow of participants, example, 162
    websites, 167
  retention, 168–71
    and alternative contact methods, 171
    and financial compensation, 169, 173
    and long periods between study visits, 169–71
    methods to improve, 293
    study flexibility, 171
  right to leave the study, 173
  special populations, 168
    staff role, 163–64
    See also adherence
  reducing bias. See bias, avoiding

relational databases, 359, 360–61
research
  broad issues in, 3–4
    assessment of success, 4, 11–12
    capability to achieve goal, 4, 10–11
    justification of research, 4, 9
    reasons for doing, 3–4, 5–7
  ethical issues in, 12–13
  issues to address before starting, 3–13
  key points, 13
  See also research question
research question, 4, 7–8
  abstract as way to clarify, 7–8
  framing may limit designs, 54–57
  multiple designs possible for one, 119–20
  multiple research questions from a single study, 53–54
  impact on design selected, 53–57, 63–64, 119–20
  resource issues, 123–24. See also economic issues; time considerations
  retention. See recruitment and retention
restractive cohort study, 82–83, 90–92
  advantages of, 86–87
  data collection, 104
  data quality issues, 129
  vs. prospective cohort study, 90–92, 127–29
  resource issues, 124
  speed of results, 129
  study time line, 302–04
  See also cohort study
risk-benefit ratio, 21, 60–61
  and blinding, 268
  and Institutional Review Board (IRB), 58, 60–61
  and interventional study, 122
  and randomization, 243–44
Index

safety variables, 178
and blinding, 266–67
ethical issues, 185
in interventional study, 179
in observational study, 181–82
sample size, 390–401
alternative way of thinking about, 398–99
calculating, 391–92
effect size, 392
ethical issues, 400–01
importance of, 390–91
“just right” number for calculating, 391–92
clinically important difference, 393–94
magical thinking and, 398–99
problem with, 393–94
ways to decrease, legitimate, 394–97
change endpoint, 394–95
decrease power, 397
modify statistical characteristics, 397
reduce variability between individuals, 396
reduce variability of measurements, 395–96
key points, 401
noise, 392
ratio of, between different groups, 399–400
variability, 392
scientific validity, as ethical issue, 19–20. See also validity
scoring of structured interviews, 349. See also raters
selecting design. See design selection
selection bias, 206–08
single arm study, 47–48, 64 64–66
clinical trial phase, 53, 65–66
disadvantages of, 64 64–66
more than one group, 67 66–68
for rare disease with uniformly poor outcome, 65
with sequential groups, 65–66
single-blind study, 262–64. See also blinding
speakers of foreign languages
and informed consent, 35, 40, 148
and questionnaires, 347–48
recruitment of, 168
special populations
and informed consent, 38–41
children, 35, 38–39
persons unable to understand and agree to study, 39
pregnant women, fetuses, neonates, 31, 40–41
prisoners, 41
speakers of other languages, 35, 40
recruitment of, 168
See also study population
spreadsheets. See data storage
staff, importance of, 168–71, 289
“standard” diet, defining, 315
Standards for Privacy of Individually Identifiable Health Information (Privacy Rule), 17–18, 24, 298, 372
storage stepped wedge design, 79
statistical significance
vs. clinical importance, 380
determining, 383–86
See also hypothesis testing; sample size
statistics, 12
validity of, 144
stepped wedge design, 79
storage. See data storage
stratification, 250–52
benefits and pitfalls with, 254–55
defining study strata, 250–51
stratification (cont.)
  implementation, 251–52
  reasons for, 250
structured interviews
  bias reduced with, 219, 223
  as data collection instrument, 345
  example of, 150–51, 223
  scoring of, 349
  and training of assessors, 223–24
study design, 47–61
  ethics and, 59–61
  key points, 61
  See also design selection; interventional
  study; observational study
Study ID, 246, 343–44, 372
study population, 147–60
  coercion of family members to
  participate, 159
  exclusion of subgroups, 158–59
  informed consent, 158
  screening procedures, order of 159
  inclusion and exclusion criteria, 148–57
  ability to communicate with participant
  as, 157
  availability for study as, 157
  in case-control study, 313–16
  in comparative cohort study, 304–05
  contraceptives, 154–55
demographics, 152
diagnosis as, 150–52
  exclusion criteria, 148
    common categories of, 149
  family history, 154
  inclusion criteria, 148
    common categories of, 149
    informed consent, 148–49
  lifestyle factors, 156–57
medical history, 153–54
  medications, 149
  physical examination, 152–53, 155–56
  suitability, 238
  individuals actually studied, 157–58
  key points, 159–60
  study group, 157–58
  study pool, 147
  See also case-control study; participant
  identification; cohort study;
  participant identification
  superiority study, 63, 71, 379–80
  surrogate variables, 193–95
time considerations, 123, 129
time-related outcomes, 192–94
time to event, 193
time trends, 192–93
tissue samples, 41–42
Type I (α) error, 380–81. See also hypothesis
testing
Type II error (β), 381–82. See also hypothesis
testing
unbalanced randomization, 255–56
unblinded study, 264–66. See also blinding
underreporting of adverse events, 209, 308
undue influence, and informed consent, 37–38
unequal randomization, 253, 255–56, 399
United Nations Educational, Scientific and
  Cultural Organization (UNESCO), 15
United States Public Health Service, 23
US Code of Federal Regulations (45 CFR
  46.116), 37
validity, 143–44
  definition, 137, 143
drop-out rate, 70
Index

ethical issues, 19–20, 145
key points, 146
in multi-site study, 354–55
scientific, as ethical issue, 19–20
and study population, 139–40, 143
See also generalizability
variables, 175–86
baseline value of, 176
binary, 175, 190–91
in case-control study, 182
in cohort study, 181
confounding (see predictor and confounding variables)
defining, 175
dichotomous, 175, 190–91
ethical issues, 185
field in database, 358
in interventional study, 176–81
key points, 186
measuring, 183–84
in observational study, 181–82
ordered categorical, 175
outcome (see outcome variables)
predictor (see predictor and confounding variables)
prognostic, 240, 249–50
recoding, 184, 190–92
safety (see safety variables)
storing (see data storage)
surrogate, 193–95
types of, 175–76
unordered categorical variable, 175–76
women
exclusion from study as ethical issue, 158
and informed consent, 31, 40–41
World Health Organization (WHO), 15, 26
World Medical Association, 15